The preclinical phase - Interpharma

Leader in research and development

The preclinical phase

The investment and time required to develop a new medicinal product is substantial – and success depends on many factors.

Overview Authorisation and product launch The clinical phase The first steps towards a new medicinal product The preclinical phase

An active substance candidate has to undergo a preclinical development programme before it can be administered to humans in clinical trials. In this programme, the substance is tested for possible harmful effects, such as whether it is toxic, causes cancer or modifies the genetic material. These tests are performed first in cell cultures and then in animal studies.

It may not be tested in humans until it has passed all the required preclinical tests. The tests in cell cultures and animals that document its harmlessness are performed in accordance with internationally accepted guidelines (ICH guidelines) which in turn are based on the 3R principles of Replace, Reduce and Refine.

The preclinical phase comprises the following studies:

  • pharmacological studies,
  • general toxicity studies,
  • toxicokinetic and pharmacokinetic studies and
  • multiple-dose toxicity studies.

Other preclinical studies are carried out in some cases depending on the specific conditions. These include an assessment of phototoxicity (when a skin response is triggered by exposure to light).

Further information

About us

Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.

Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.

Annual report

Information on our key figures and activities in the financial year 2023

read more

Board and Executive Management

Introducing Interpharma

read more

Vision and Mission

More about the tasks and overriding aims of Interpharma

read more


Contact us

read more


Latest information and media contacts for media representatives

read more